ClinicalTrials.gg
Status unknownNCT04759651Updated Apr 15, 2022

Sleep Disorders in Patients With Suspected Lung Cancer Before and After Thoracic Surgery

An observational study in Lung Cancer, sponsored by Koç University. Status unknown at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-15.

Sponsored by Koç University · Observational

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Study summary

The main aim of this study is to prospectively evaluate the occurrence of sleep disorders in patients undergoing thoracic surgery due to the preliminary diagnosis of lung cancer. Secondary aims include anxiety, depressive mood and functional outcomes before and 3 months after the intervention.

Read the detailed description

Cancer surgery is one of the traumas that affect human life, starting from diagnostic procedures, along with the recovery process. Although 5-year survival in lung cancer has increased to 60%, there is a general prejudice that lung cancer has a poor prognosis. A preliminary diagnosis of a such condition has consequently a negative effect on the mood and sleep patterns of the patients, starting already from the beginning of the diagnostic procedures. In our study, we want to evaluate the occurrence of sleep disorders, anxiety, depressive mood and functional outcomes before and 3 months after the surgical intervention. This would also help us to better identify the patients in need for professional support for sleep disorders as well as psychiatric conditions, and thus, a better management of patients with lung cancer.

02

Conditions studied

  • Lung Cancer

Keywords

  • sleep disorder
  • vats
  • lung cancer
  • robotics
  • thoracoscopy
03

In context

Lung Neoplasms

7,334 studies on the registry are indexed under Lung Neoplasms; 1,554 are open to participants now.

This study's planned enrollment of 1,200 is above the median of 190 across 1,547 observational studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

Koç University is the lead sponsor of 109 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients meeting the criteria will be included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who will undergo lung resection with a pre-diagnosis of lung cancer
  • Being literate or having the physical strength to answer questions.

Exclusion criteria

Exclusion Criteria:

  • The patient has a chronic disease such as dementia or treatment-resistant schizophrenia in which reality assessment is impaired.
  • Patients who have received chemotherapy and / or radiotherapy due to their previous disease.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No

Interventions

  • OtherFunctional Outcome of Sleep Questionnaire Turkish version (FOSQ-TR)

    Sleep related quality of life questionnaire.

  • OtherEpworth Sleepiness Scale (ESS)

    Subjective level of daytime sleepiness.

  • OtherBerlin Questionnaire

    Evaluation of high-risk for Obstructive Sleep Apnea.

  • OtherStop-Bang Questionnaire

    Evaluation of high-risk Obstructive Sleep Apnea.

  • OtherInsomnia Questionnaire

    Subjective evaluation of insomnia.

  • OtherRestless Leg Syndrome Questionnaire

    Subjective evaluation of Restless Leg Syndrome.

  • OtherZung Self-rating Depression Scale (SDS)

    Subjective test for evaluation of depressive mood.

  • OtherBeck Anxiety Inventory

    Subjective test for evaluation of anxiety.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Functional Outcome of Sleep Questionnaire scores

    Sleep related quality of life. Score range: 5-20 points, with higher scores indicating better functional status.

    Time frame: 3 months

  2. Change from baseline in Epworth Sleepiness Scale scores

    Excessive daytime sleepiness. Score range: 0-24 points, with higher scores indicating greater daytime sleepiness. Scores ≥11 are generally considered to be abnormal, or positive for excessive daytime sleepiness.

    Time frame: 3 months

  3. Change from baseline in Berlin Questionnaire scores

    High-risk Obstructive Sleep Apnea. Patients can be classified into High Risk or Low Risk based on their responses to the individual items and their overall scores in the symptom categories.

    Time frame: 3 months

  4. Change from baseline in STOP-BANG questionnaire scores

    High-risk Obstructive Sleep Apnea. Score range: 0-8 points, patients with a STOP-Bang score of 0 to 2 can be classified as low risk for moderate to severe OSA whereas those with a score of 5 to 8 can be classified as high risk for moderate to severe OSA. The STOP-BANG is an assessment tool used to help diagnose Obstructive Sleep Apnea

    Time frame: 3 months

  5. Change from baseline in Insomnia questionnaire scores

    Insomnia questionnaire. Score range: 0-28 points, with higher scores indicating greater insomnia severity.

    Time frame: 3 months

  6. Change from baseline in Restless Legs Syndrome questionnaire scores

    Restless Leg Syndrome questionnaire. Score range: 0-4 points, with higher scores indicating more severe symptoms

    Time frame: 3 months

Secondary outcomes

  1. Change from baseline in Zung Self-rating Depression Scale scores

    Zung Self-rating Depression Scale. Score range: 0-80 points, most people with depression score between 50 and 69, while a score of 70 and above indicates severe depression.

    Time frame: 3 months

  2. Change from baseline in Beck Anxiety Inventory scores

    Self-rating anxiety scale. Score range: 0-63 points, a total score of 0 - 7 is interpreted as a "Minimal" level of anxiety; 8 - 15 as "Mild"; 16 - 25 as "Moderate", and; 26 - 63 as "Severe".

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Koç University Hospital
    Istanbul, 34010, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data collected for the study, including de-identified individual participant data will be made available to others within 6 months after the publication of this article, as will additional related documents (study protocol, statistical analysis plan, and informed consent form), for academic purposes (e.g., meta-analyses), upon request to the corresponding author, and with a signed data access agreement

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 6 months after the publication of the results

Access criteria: Data collected for the study, including de-identified individual participant data will be made available to others within 6 months after the publication of this article, as will additional related documents (study protocol, statistical analysis plan, and informed consent form), for academic purposes (e.g., meta-analyses), upon request to the corresponding author (serus@ku.edu.tr), and with a signed data access agreement.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04759651
Lead sponsor
Koç University
Collaborators
Marmara University, Trakya University, Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Yedikule Training and Research Hospital, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Responsible party
Sponsor
First posted
Feb 18, 2021
Start date
Jun 1, 2021
Primary completion
Dec 31, 2022 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Apr 15, 2022

Study contacts

Suat Erus, MD
Contact
serus@ku.edu.tr
+905325506947
Hale Yapıcı Eser, MD
Contact
hyapici@ku.edu.tr
+908502508250

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion